{"id":"NCT01266993","sponsor":"GlaxoSmithKline","briefTitle":"Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children","officialTitle":"Persistence of Antibodies After Vaccination With a Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children and Safety and Immunogenicity of a Booster Dose at 68 Months Post-primary Vaccination","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01-03","primaryCompletion":"2014-03-31","completion":"2014-05-17","firstPosted":"2010-12-24","resultsPosted":"2019-01-31","lastUpdate":"2020-11-23"},"enrollment":271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal","Meningococcal Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Nimenrix (GSK134612 vaccine)","otherNames":[]},{"type":"BIOLOGICAL","name":"Menjugate","otherNames":[]}],"arms":[{"label":"Nimenrix Group","type":"EXPERIMENTAL"},{"label":"Menjugate Group","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the persistence of the immune response of GSK134612 vaccine up to 68 months after vaccination in the primary vaccination study (NCT number = NCT00674583) of 2 to 10 year old subjects. This study will also evaluate the safety and immunogenicity of a booster dose of GSK134612 vaccine subjects who were primed in the primary vaccination study with either GSK134612 vaccine or Menjugate®.\n\nThis protocol posting deals with objectives \\& outcome measures of the persistence and booster epochs. The objectives \\& outcome measures of the primary epoch are presented in a separate protocol posting (NCT number = NCT00674583)","primaryOutcome":{"measure":"Number of Subjects With Serum Bactericidal Assay, Using Baby Rabbit Complement, Against Neisseria Meningitides Serogroup A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Antibody Titers Was Greater Than or Equal to (≥) 1:8, at Month 32.","timeFrame":"At Month 32, post-primary vaccination","effectByArm":[{"arm":"Nimenrix Group","deltaMin":167,"sd":null},{"arm":"Menjugate Group","deltaMin":15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":24,"countries":["France","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":179},"commonTop":["Pain","Erythema","Swelling","Headache","Fatigue"]}}